Lack of Health Insurance Limits the Benefits of Hepatitis C Virus Screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study

Ditah, Ivo; Bawardy, Badr Al; González, Humberto C.; Saberi, Behnam; Ditah, Callistus; Kamath, Patrick S.; Charlton, Michael

doi:10.1038/ajg.2015.31

Cited by 32 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study revealed barriers throughout the care continuum that discourage utilization within this population. Echoing prior research (Ditah et al, 2015), high costs were noted as obstacles to pursuing and adhering to treatment, which reinforced deeply entrenched barriers in this community, namely that patients were undeserving of care and were unlikely to receive it. Interactions with providers, including perceived doubt associated with PWID’s ability and willingness to adhere to treatment also reinforced these beliefs.…”

Section: Discussionmentioning

confidence: 92%

‘Hep C’s like the common cold’: understanding barriers along the HCV care continuum among young people who inject drugs

Skeer

Ladin

Wilkins

et al. 2018

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

‘Hep C’s like the common cold’: understanding barriers along the HCV care continuum among young people who inject drugs

Skeer

Ladin

Wilkins

et al. 2018

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…Now that all-oral, curative treatment for HCV is available, HCV testing of people born in 1945-1965 is recommended[ 52 ]. Nevertheless, barriers to HBV and HCV testing and treatment remain[ 21 , 53 - 55 ]. However, attempts to intentionally link HBV screening results with linkage to care, while not optimized yet, are promising[ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012

Stewart

Kwong

Bowlus

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo describe racial/ethnic differences in treatment and survival among liver cancer patients in a population-based cancer registry.METHODSInvasive cases of primary hepatocellular carcinoma, n = 33270, diagnosed between January 1, 1988-December 31, 2012 and reported to the California Cancer Registry were analyzed by race/ethnicity, age, gender, geographical region, socio-economic status, time period of diagnosis, stage, surgical treatment, and survival. Patients were classified into 15 racial/ethnic groups: non-Hispanic White (White, n = 12710), Hispanic (n = 8500), Chinese (n = 2723), non-Hispanic Black (Black, n = 2609), Vietnamese (n = 2063), Filipino (n = 1479), Korean (n = 1099), Japanese (n = 658), American Indian/Alaskan Native (AIAN, n = 281), Laotian/Hmong (n = 244), Cambodian (n = 233), South Asian (n = 190), Hawai`ian/Pacific Islander (n = 172), Thai (n = 95), and Other Asian (n = 214). The main outcome measures were receipt of surgical treatment, and cause-specific and all-cause mortality.RESULTSAfter adjustment for socio-demographic characteristics, time period, and stage of disease, compared to Whites, Laotian/Hmong [odds ratio (OR) = 0.30, 95%CI: 0.17-0.53], Cambodian (OR = 0.65, 95%CI: 0.45-0.96), AIAN (OR = 0.66, 95%CI: 0.46-0.93), Black (OR = 0.76, 95%CI: 0.67-0.86), and Hispanic (OR = 0.78, 95%CI: 0.72-0.84) patients were less likely, whereas Chinese (OR = 1.58, 95%CI: 1.42-1.77), Koreans (OR = 1.45, 95%CI: 1.24-1.70), Japanese (OR = 1.41, 95%CI: 1.15-1.72), and Vietnamese (OR = 1.26, 95%CI: 1.12-1.42) were more likely to receive surgical treatment. After adjustment for the same covariates and treatment, cause-specific mortality was higher for Laotian/Hmong [(hazard ratio (HR) = 1.50, 95%CI: 1.29-1.73)], Cambodians (HR = 1.35, 95%CI: 1.16-1.58), and Blacks (HR = 1.07, 95%CI: 1.01-1.13), and lower for Chinese (HR = 0.82, 95%CI: 0.77-0.86), Filipinos (HR = 0.84, 95%CI: 0.78-0.90), Vietnamese (HR = 0.85, 95%CI: 0.80-0.90), Koreans (HR = 0.90, 95%CI: 0.83-0.97), and Hispanics (HR = 0.91, 95%CI: 0.88-0.94); results were similar for all-cause mortality.CONCLUSIONDisaggregated data revealed substantial racial/ethnic differences in liver cancer treatment and survival, demonstrating the need for development of targeted interventions to mitigate disparities.

show abstract

“…Blood transfusions are a major source of HCV in some countries such as India (153,169). Among those who are already infected with HBV or HCV, a reduction in risk of liver cancer has been shown with the use of antiviral treatments; however, antiviral treatments for chronic HBV and HCV infections have a high cost (170,171) and are often beyond the reach of the majority of patients in LMICs (172)(173)(174), and even a substantial proportion of the population in HICs (175,176). Because of these cost barriers, the most cost-effective approach in most parts of the world remains prevention of HBV and HCV infections.…”

Section: Liver Cancermentioning

confidence: 99%

Global Cancer in Women: Burden and Trends

Torre

Islami

Siegel

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

1,034

728

View full text Add to dashboard Cite

There are striking disparities in the global cancer burden in women, yet few publications highlight cancer occurrence in this population, particularly for cancers that are not sex specific. This article, the first in a series of two, summarizes the current burden, trends, risk factors, prevention, early detection, and survivorship of all cancers combined and seven sites (breast, cervix, uterine corpus, ovary, colorectum, lung, and liver) that account for about 60% of the cancer burden among women worldwide, using data from the International Agency for Research on Cancer. Estimated 2012 overall cancer death rates in general are higher among women in low- and middle-income countries (LMICs) than high-income countries (HICs), despite their lower overall incidence rates, largely due to inadequate access to early detection and treatment. For example, the top mortality rates are in Zimbabwe (147 deaths per 100,000) and Malawi (138). Furthermore, incidence rates of cancers associated with economic development (e.g., lung, breast, colorectum) are rising in several LMICs. The burden of cancer among women could be substantially reduced in both HICs and LMICs through broad and equitable implementation of effective interventions, including tobacco control, HPV and HBV vaccination, and screening (breast, cervix, and colorectum).

show abstract

Lack of Health Insurance Limits the Benefits of Hepatitis C Virus Screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study

Abstract: This study suggests that the lack of health insurance may attenuate the theoretical benefits of a screening program that identifies asymptomatic HCV-infected individuals who are less likely to pursue downstream care.

Cited by 32 publications

References 33 publications

‘Hep C’s like the common cold’: understanding barriers along the HCV care continuum among young people who inject drugs

‘Hep C’s like the common cold’: understanding barriers along the HCV care continuum among young people who inject drugs

Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012

Global Cancer in Women: Burden and Trends

Contact Info

Product

Resources

About